Gracell Biotechnologies Investor Relations Material
Latest events
Q3 2023
Gracell Biotechnologies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Gracell Biotechnologies Inc
Access all reports
Gracell Biotechnologies Inc. (GRCL) is a clinical-stage biopharmaceutical company primarily focused on discovering and developing innovative cell therapies for cancer treatment. The company leverages its proprietary FasTCAR and TruUCAR technology platforms, along with its SMART CART™ technology module, to develop therapies designed to offer fast, deep, and durable responses for patients suffering from cancer and autoimmune diseases. Gracell Biotechnologies is headquartered in Suzhou, China, and its shares are listed on the Nasdaq.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
GRCL
Country
🇺🇸 United States